Anna Brown, News Reporter at Endpoints News, interviewed Natalia Elizalde, Chief Business Development Officer, to obtain VIVEbiotech’s perspective on the matter. The article emphasizes the need to address manufacturing challenges to avoid a potential shortage of lentiviral vectors as gene therapies become more prevalent in the market.
As Natalia stated, we at VIVEbiotech anticipate lentiviral vector demand to go up as these vectors are used in wider applications, such as in CAR-Ts, vaccines and solid tumor treatment. She adds that on top of adding additional production capacity, we at VIVEbiotech are working on our process to increase manufacturing productivity.
The resulting article in which experts from Lonza, bluebird bio, Thermo Fisher Scientific and Johnson & Johnson do also participate was featured as the top article in the Endpoints News´s manufacturing newsletter. It can be read here: https://endpts.com/lentiviral-vector-shortage-looms-unless-manufacturing-hurdles-from-clinical-to-commercial-are-addressed/
Many thanks to Endpoints News and Anna Brown for raising our voice.